The MNKs; Novel Markers of Type 2 Diabetes Mellitus Risk v1.0

• Research type

  Research Study

• Full title

  The MAPK-serine/threonine interacting kinases (MNKs); Novel Markers of Type 2 Diabetes Mellitus Risk.

• IRAS ID

  198423

• Contact name

  Rebecca Stead

• Contact email

  rebeccastead@nhs.net

• Sponsor organisation

  University of Manchester

• Duration of Study in the UK

  1 years, 0 months, 1 days

• Research summary

  The cost of type II diabetes mellitus (T2DM) to the national health service (NHS) is increasing significantly year on year and is projected to equate to 15% of the NHS budget by 2035. Diagnosis of T2DM involves testing the blood for glucose and another marker called HbA1c. However, there is not yet a marker for T2DM risk in the population whose lifestyle choices and family history indicate an increased likelihood of developing T2DM.
  The MNKs are signalling proteins involved in cell growth and inflammation but also the control of blood glucose levels.
  Initial research shows mice without the MNKs are protected from high-fat diet-induced T2DM. It is expected that overweight/obese people with T2DM will have high blood levels of the MNKs and therefore the MNKs may represent a useful marker of T2DM risk in populations with poor lifestyle choices who are overweight/obese.

• REC name

  South Central - Oxford B Research Ethics Committee

• REC reference

  16/SC/0257

• Date of REC Opinion

  6 May 2016

• REC opinion

  Favourable Opinion